Danielle Smith Laughlin, DVM, DACVIM (cardiology): No relevant disclosure to display
Presentation Description / Summary: The anthracycline drug doxorubicin has historically been one of the top chemotherapy choices for successful treatment of common canine cancers such as lymphoma & hemangiosarcoma. However, its effects on the heart can lead to severe cardiac toxicity including dilated cardiomyopathy and arrhythmias. This is often complicated by the effects of cancer on the heart itself. In addition, many canine breeds prone to cancer are unfortunately also at risk for heart disease. This creates both a unique challenge and opportunity in veterinary medicine that crosses the specialties of cardiology and oncology. The first part of this interactive lecture will provide a critical review of current literature of anthracycline-induced cardiotoxicity. The second part of the lecture will include a tandem case-based approach to optimizing successful treatment and patient care. Focus will be on cardiologist’s perspective regarding underlying heart disease that could be worsened with doxorubicin treatment, early detection of doxorubicin cardiotoxicity, and cardiac medical management as well as oncologist’s perspectives on modifying chemo protocols and alternative chemo options to balance effectiveness and patient safety.
Learner Outcomes: Describe types of underlying heart disease that could potentially be worsened with doxorubicin treatment
Discuss cardiac medical management with clients
List potential modifications and alternatives to standard doxorubicin chemo protocols
